دورية أكاديمية
أعرض في EDS

Establishment and Comprehensive Molecular Characterization of an Immortalized Glioblastoma Cell Line from a Brazilian Patient.

التفاصيل البيبلوغرافية
العنوان: Establishment and Comprehensive Molecular Characterization of an Immortalized Glioblastoma Cell Line from a Brazilian Patient.
المؤلفون: da Silva FF; International Research Center/CIPE, A.C. Camargo Cancer Center, São Paulo 01508-010, Brazil.; National Institute of Science and Technology in Oncogenomics (INCITO), São Paulo 01509-900, Brazil., Lupinacci FCS; International Research Center/CIPE, A.C. Camargo Cancer Center, São Paulo 01508-010, Brazil.; National Institute of Science and Technology in Oncogenomics (INCITO), São Paulo 01509-900, Brazil., Elias BDS; International Research Center/CIPE, A.C. Camargo Cancer Center, São Paulo 01508-010, Brazil.; National Institute of Science and Technology in Oncogenomics (INCITO), São Paulo 01509-900, Brazil., Beserra AO; International Research Center/CIPE, A.C. Camargo Cancer Center, São Paulo 01508-010, Brazil.; National Institute of Science and Technology in Oncogenomics (INCITO), São Paulo 01509-900, Brazil., Sanematsu P; Neurosurgery Department, A.C. Camargo Cancer Center, São Paulo 01509-010, Brazil., Roffe M; Children's Hospital of Eastern Ontario Research Institute, Ottawa, ON K1H 8L1, Canada., Kulikowski LD; Cytogenomics Laboratory, Hospital das Clínicas da Faculdade de Medicina, Universidade de São Paulo, São Paulo 05403-010, Brazil., Costa FD; Department of Anatomic Pathology, A.C. Camargo Cancer Center, São Paulo 01509-010, Brazil., Santos TG; International Research Center/CIPE, A.C. Camargo Cancer Center, São Paulo 01508-010, Brazil.; National Institute of Science and Technology in Oncogenomics (INCITO), São Paulo 01509-900, Brazil., Hajj GNM; International Research Center/CIPE, A.C. Camargo Cancer Center, São Paulo 01508-010, Brazil.; National Institute of Science and Technology in Oncogenomics (INCITO), São Paulo 01509-900, Brazil.
المصدر: International journal of molecular sciences [Int J Mol Sci] 2023 Nov 01; Vol. 24 (21). Date of Electronic Publication: 2023 Nov 01.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI, [2000-
مواضيع طبية MeSH: Glioblastoma*/metabolism , Brain Neoplasms*/metabolism, Adult ; Humans ; Brazil ; Cell Line, Tumor ; Tubulin/metabolism
مستخلص: Glioblastoma (GBM) is the most common and aggressive primary brain tumor in adults, with few effective treatment strategies. The research on the development of new treatments is often constrained by the limitations of preclinical models, which fail to accurately replicate the disease's essential characteristics. Herein, we describe the obtention, molecular, and functional characterization of the GBM33 cell line. This cell line belongs to the GBM class according to the World Health Organization 2021 Classification of Central Nervous System Tumors, identified by methylation profiling. GBM33 expresses the astrocytic marker GFAP, as well as markers of neuronal origin commonly expressed in GBM cells, such as βIII-tubulin and neurofilament. Functional assays demonstrated an increased growth rate when compared to the U87 commercial cell line and a similar sensitivity to temozolamide. GBM33 cells retained response to serum starvation, with reduced growth and diminished activation of the Akt signaling pathway. Unlike LN-18 and LN-229 commercial cell lines, GBM33 is able to produce primary cilia upon serum starvation. In summary, the successful establishment and comprehensive characterization of this GBM cell line provide researchers with invaluable tools for studying GBM biology, identifying novel therapeutic targets, and evaluating the efficacy of potential treatments.
References: Nature. 2019 May;569(7757):503-508. (PMID: 31068700)
Front Cell Neurosci. 2019 Feb 20;13:55. (PMID: 30842728)
J Histochem Cytochem. 2018 Jun;66(6):403-414. (PMID: 29328863)
Methods Mol Biol. 2018;1741:183-190. (PMID: 29392700)
Front Oncol. 2021 Apr 26;11:621432. (PMID: 33981597)
N Engl J Med. 2023 Aug 17;389(7):589-601. (PMID: 37272516)
Cell. 2013 Oct 10;155(2):462-77. (PMID: 24120142)
Mol Cancer Res. 2008 Jan;6(1):21-30. (PMID: 18184972)
Oncogene. 2018 Mar;37(11):1457-1471. (PMID: 29321663)
Nat Rev Nephrol. 2019 Apr;15(4):199-219. (PMID: 30733609)
Neuro Oncol. 2021 Aug 2;23(8):1231-1251. (PMID: 34185076)
PLoS One. 2013 Jul 02;8(7):e68521. (PMID: 23844214)
Cancer Cell. 2006 May;9(5):391-403. (PMID: 16697959)
Spermatogenesis. 2012 Jan 1;2(1):1-5. (PMID: 22553484)
JAMA Oncol. 2022 Oct 1;8(10):1493-1501. (PMID: 36006639)
J Vis Exp. 2014 Oct 27;(92):e51998. (PMID: 25408172)
Sci Transl Med. 2016 Aug 31;8(354):354re3. (PMID: 27582061)
Cancer Res. 2013 Apr 1;73(7):2259-70. (PMID: 23370327)
Neuro Oncol. 2016 Mar;18(3):350-60. (PMID: 26245525)
BMC Clin Pathol. 2014 Sep 12;14:40. (PMID: 25228849)
Cilia. 2018 Nov 06;7:6. (PMID: 30410731)
Nature. 2018 Mar 22;555(7697):469-474. (PMID: 29539639)
J Neurooncol. 2014 Mar;117(1):15-24. (PMID: 24510433)
Front Oncol. 2020 Jan 17;9:1547. (PMID: 32010632)
Neuro Oncol. 2019 Nov 1;21(Suppl 5):v1-v100. (PMID: 31675094)
Nat Med. 2009 Sep;15(9):1062-5. (PMID: 19701203)
BMC Cancer. 2009 Dec 17;9:448. (PMID: 20017937)
PLoS One. 2013;8(2):e57462. (PMID: 23468990)
Oncotarget. 2016 Feb 9;7(6):7029-43. (PMID: 26760767)
Nat Rev Cancer. 2018 Aug;18(8):511-524. (PMID: 29802351)
Cancer Res. 2009 Jan 15;69(2):422-30. (PMID: 19147554)
BMC Cancer. 2011 Dec 20;11:524. (PMID: 22185371)
Transl Oncol. 2016 Oct;9(5):392-402. (PMID: 27661404)
Cancer Rep (Hoboken). 2021 Apr;4(2):e1324. (PMID: 33251771)
PLoS One. 2012;7(10):e47741. (PMID: 23077666)
Cilia. 2013 Jan 31;2(1):2. (PMID: 23369289)
Ther Adv Med Oncol. 2018 Oct 03;10:1758835918801169. (PMID: 30302130)
N Engl J Med. 2005 Mar 10;352(10):987-96. (PMID: 15758009)
Arch Med Sci. 2020 Feb 04;16(2):481-483. (PMID: 32190162)
معلومات مُعتمدة: 2020/14045-0 São Paulo Research Foundation
فهرسة مساهمة: Keywords: Akt; cell lines; copy number variation; glioblastoma; mTOR; methylation profile; primary cilia
المشرفين على المادة: 0 (Tubulin)
تواريخ الأحداث: Date Created: 20231114 Date Completed: 20231115 Latest Revision: 20231117
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC10649167
DOI: 10.3390/ijms242115861
PMID: 37958846
قاعدة البيانات: MEDLINE
الوصف
تدمد:1422-0067
DOI:10.3390/ijms242115861